An interventional study of Sauna in Heart Failure, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Heart Failure by Central Hospital, Nancy, France — 9 open to participants now, 10 under way, 1 of them phase 3. Heart Failure · Central Hospital, Nancy, France.
Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, this one is the 12th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 19th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →9 of the 19 studies in Heart Failure by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 103 across the 13 interventional studies, 207 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
3 of the studies in Heart Failure by Central Hospital, Nancy, France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT06868797Central Hospital, Nancy, FranceAcute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List | 2027-02-28 |
| NCT07468344Central Hospital, Nancy, FranceEvaluation of the Effects of Sauna Therapy on Congestion and Loop Diuretic Use in Patients With Heart Failure With Reduced or Moderately Reduced Ejection Fraction | 2027-09-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effect of sauna therapy on congestion levels during cardiac rehabilitation in patients with heart failure who have an impaired or moderately impaired ejection fraction, compared to standard cardiac rehabilitation care. To investigate this, patients with reduced cardiac function who are hospitalized as part of a cardiac rehabilitation program will be included. These patients will be randomly assigned to two groups: standard cardiac rehabilitation program (control group) and sauna group (intervention group). The study will also assess whether this approach could allow for a reduction in the dose of diuretics, which are commonly used to remove excess fluid, thereby helping to avoid certain side effects. The expected benefits include a reduction in symptoms such as shortness of breath and swelling, improvements in quality of life and physical fitness, and enhanced blood vessel function.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 15-minute sauna session at 60 degrees Celsius during hospitalization for cardiac rehabilitation.
Device: Sauna
Usual care as part of a day hospital stay for cardiac rehabilitation.
A 15-minute sauna session at 60 degrees Celsius, five times a week for three weeks during hospitalization for cardiac rehabilitation. The sauna sessions will be followed by 30 minutes of recovery in a seated position. In addition to the sauna, patients will benefit from cardiac rehabilitation care for 3 weeks.
Median change in NT-proBNP levels.
Time frame: Between randomization and the end of the third week.
Daily dose of loop diuretics.
Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Weight in kilograms.
Time frame: Day 1, end of weeks 1,2 and 3, and 3-month follow-up.
Congestion score: ADVoR congestion score.
ADVoR congestion score is a grading scale taking account oedema, pleural effusion and ascites. The score can range from 0 to 10 with "0" being the best result meaning " no congestion " and "10" the worst meaning " maximum congestion ".
Time frame: Day 1, end of week 3, and 3-month follow-up.
Congestion score: Ambrosy congestion score.
Ambrosy congestion score is a grading scale taking account dyspnoea, orthopnoea, jugular venous distension, rales and oedema. The score can range from 0 to 18, "0" being the best outcome (no congestion) and "18" the worst outcome (maximum congestion).
Time frame: Day 1, end of week 3, and 3-month follow-up.
Estimated plasma volume (EPV): Duarte formula.
Time frame: Day 1, end of week 3, and 3-month follow-up.
Dyspnea visual analog scale: Cumulative dyspnea assessment (AUC).
The minimum value is "0" (best outcome) and means "no dyspnea". The maximum value is "10" (worst outcome) and means "maximum dyspnea".
Time frame: Day 1, beginning of weeks 2 and 3.
Concentration of natriuretic peptides (NT-proBNP).
Time frame: Day 1, end of week 1, beginning and end of week 2, beginning and end of week 3, and 3-month follow-up.
Evaluation of renal function through rate of serum creatinine allowing to estimate glomerular filtration rate.
Estimate glomerular filtration rate is calculated by the following formula : Clearance (mL/min) = weight (kg) x (140-age) x K / serum creatinine (μmol/L) ; K=1.23 for man and 1.04 for woman.
Time frame: End of weeks 1, 2, and 3 and 3-month follow-up.
Evaluation of renal function through renal function assessment.
Time frame: Day 1 and end of week 3.
Dose of diuretics.
Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Concentration of serum electrolytes (Cl-, Na+, K+).
Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Blood osmolality in mmol/L.
Blood osmolality in mmol/L is calculated using natremia, glycemia and uremia. The formula is : Natremia in mmmol/L\*2 + glycemia in mmol/L \*5.56 + uremia in mmol/L\*16.6.
Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Concentration of urinary electrolytes (Cl-, Na+, K+).
Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Urinary osmolality in mmol/L.
Urinary osmolality in mmol/L is calculated using natremia, glycemia and uremia. The formula is : (natremia in mmol/L + kaliemia in mmol/L+ chloride in mmol/L) + (glycemia in mmol/L\*5.56) + (uremia in mmol/L\*16.6).
Time frame: Day 1, beginning and end of weeks 1, 2, and 3, and 3-month follow-up.
Hemoconcentration biomarkers : Hct.
Hemoconcentration was assessed using hematocrit (%).
Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Hemoconcentration biomarkers : Hb.
Hemoconcentration was assessed using hemoglobin (g/dL).
Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Hemoconcentration biomarkers : total protein.
Hemoconcentration was assessed using total protein (g/L).
Time frame: Time Frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Hemoconcentration biomarkers : copeptin.
Hemoconcentration was assessed using copeptin concentrations (pmol/L).
Time frame: Time Frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.
Inferior vena cava diameter (millimeters, mm) measured by transthoracic echocardiography during inspiration.
The inferior vena cava (IVC) diameter will be measured in millimeters using transthoracic echocardiography.
Time frame: Day 1, end of week 1, beginning and end of week 2, beginning and end of week 3, and 3-month follow-up.
Inferior vena cava diameter (millimeters, mm) in expiration measured by transthoracic echocardiography during expiration.
IVC diameter will be measured in millimeters using transthoracic echocardiography.
Time frame: Day 1, end of week 1, beginning and end of week 2, beginning and end of week 3, and 3-month follow-up.
Inferior vena cava respiratory variation / collapsibility index (percentage, %) assessed by transthoracic echocardiography.
VCI respiratory variation will be assessed using transthoracic echocardiography and expressed as the collapsibility index. Collapsibility index will be measured as the ratio between IVC diameter in inspiration (outcome 17) and IVC diameter in expiration (outcome 18) expressed in %.
Time frame: Day 1, end of week 1, beginning and end of week 2, beginning and end of week 3, and 3-month follow-up.
Lung ultrasound score (8 points).
Evaluation of lung comet presence measured by an 8-points lung echography and rated on a scale ranging from 0 (minimum - best outcome : no congestion) to 10 (maximum - worst outcome : maximum congestion) per point.
Time frame: Day 1, end of week 3, and 3-month follow-up.
Quantification of changes in systolic and diastolic function.
Time frame: Day 1 and 3-month follow-up.
Heart rate in Beats Per Minute (BPM).
Time frame: Multiple daily measurements : 4 times a day, 5 days a week for 3 weeks.
Heart rate variability in millisecond (ms).
Time frame: Multiple daily measurements : 4 times a day, 5 days a week for 3 weeks.
Blood pressure in mmHg.
Blood pressure will be measured daily for 3 weeks and at 3-month follow-up.
Time frame: Up to 3 weeks and at 3-month follow-up.
Monitoring of changes in pulmonary blood pressure.
Changes in pulmonary blood pressure will be measured with echocardiography.
Time frame: Day 1 and at 3-month follow-up.
Composite clinical endpoint of hospitalization or emergency visits for heart failure or all-cause death.
Time frame: At 3-month follow-up.
Body composition parameters assessed by bioelectrical impedance analysis.
Evaluation of the patient's body composition parameters. This measure includes the assessment of fluid distribution-Total Body Water (TBW), Intracellular Water (ICW), and Extracellular Water (ECW)-as well as tissue compartments: body protein mass, body mineral mass, and fat mass. The device records multiple parameters, the analysis will focus specifically on these pre-specified indicators of body composition.
Time frame: Day 1, end of Week 1, beginning and end of Week 2, beginning and end of Week 3, and at 3-month follow-up.
Specific to the sauna group : weight in kilograms.
Weight will be measured before and after each sauna session.
Time frame: Up to 3 weeks.
Specific to the sauna group : blood pressure in mmHg.
Blood pressure will be measured before and after each sauna session.
Time frame: Up to 3 weeks.
Specific to the sauna group : temperature in °C.
Temperature will be measured before and after each sauna session.
Time frame: Up to 3 weeks.
Specific to the sauna group : heart rate in Beats Per Minute (BPM).
Heart rate will be measured continuously during each sauna session.
Time frame: Up to 3 weeks.
Specific to the sauna group : sodium chloride concentration in sweat.
The concentration of sodium chloride in sweat will be measured during one sauna session per week (three measurements in total).
Time frame: Up to 3 weeks.
Handgrip stenght test
Handgrip stenght will be measured using a dynamometer.
Time frame: Day 1 and at the end of Week 3.
Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 15 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Apr 2026 → Jun 2026, primary completion Jul 2027 → Sep 2027 and completion Jul 2027 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →